Novavax to Participate in Panel at BIO Digital 2021

Rhea-AI Summary

Novavax (Nasdaq: NVAX) has announced that CEO Stanley C. Erck will take part in a panel discussion at the BIO International Convention 2021 on June 14. The event, hosted by the Biotechnology Innovation Organization, is scheduled for June 10-11 and June 14-18. The panel will focus on global pandemic preparedness, featuring discussions about Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This protein-based vaccine is designed to combat SARS-CoV-2 and is currently under evaluation in multiple clinical trials.

GAITHERSBURG, Md., June 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14. BIO Digital 2021 is hosted by the Biotechnology Innovation Organization (BIO) and is taking place June 10-11 and June 14-18. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Panel details are as follows:
Date:	Monday, June 14, 2021
Time:	3:00 p.m. – 3:45 p.m. Eastern Time (ET)
Title:	Global Pandemic Preparedness – It Takes a Globe....
Moderator:	Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization
Panelists:	Stanley C. Erck, President and Chief Executive Officer, Novavax
	Amanda Glassman, Executive Vice President, Chief Executive Officer, CGD Europe and Senior Fellow, Center for Global Development
	Richard Hatchett, M.D., Chief Executive Officer, Coalition for Epidemic Preparedness
	Rajeev Venkayya, M.D., President, Global Vaccine Business Unit, Takeda Pharmaceuticals

For more information or to register for the meeting, visit: https://www.bio.org/events/bio-digital/registration.

About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax' patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.

NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the B.1.1.7/501Y.V1 variant and 89.7% overall; and the PREVENT-19 trial in the U.S. and Mexico that began in December 2020. It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 48.6% efficacy against a newly emerging escape variant first described in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.

NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.

About Matrix-M™ Adjuvant
Novavax' patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com 

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com 

Media
Laura Keenan | 202-709-7521
Alison Chartan | 240-720-7804
media@novavax.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-panel-at-bio-digital-2021-301307002.html

SOURCE Novavax, Inc.

FAQ

What will Stanley C. Erck discuss at the BIO International Convention 2021?

Stanley C. Erck will discuss global pandemic preparedness and Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

When is Novavax's presentation at the BIO Digital 2021 event?

The presentation will take place on June 14, 2021, from 3:00 p.m. to 3:45 p.m. Eastern Time.

What is NVX-CoV2373?

NVX-CoV2373 is Novavax's protein-based COVID-19 vaccine candidate, created using recombinant nanoparticle technology.

What are the efficacy results for NVX-CoV2373?

In Phase 3 trials, NVX-CoV2373 demonstrated 96.4% efficacy against the original virus strain and 86.3% against the B.1.1.7 variant.

Where can I find more information about Novavax's COVID-19 vaccine?

More information can be found on Novavax's official website or through their press release.